Ultralow Dose PET Imaging of 18F-flurpiridaz

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 200 participants.

Also called NCT07284576

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Akiva Mintz (from the registry)
Registry
  • NCT NCT07284576
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07284576. Allocation not applicable; no masking; primary purpose diagnostic. Start 2025-12-16 (actual); primary completion 2030-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ultralow Dose PET Imaging of 18F-flurpiridaz
Condition
Healthy Volunteer
Condition
Coronary Arterial Disease
Condition
Myocardial Ischemia
Intervention (Drug)
18F-flurpiridaz
Lead sponsor
Akiva Mintz (class: other)

Record details

Record id
cardio:ct-nct07284576
Content hash
95eeaa8c6dc7597132f68a7b5a0588b385e79bdc97f90bd09b8c50f5cfea7db5